Elsinga PH - Search Results

1

Fluorine-18 radiopharmaceuticals beyond [18F]FDG for use in oncology and neurosciences.

Coenen HH, Elsinga PH, Iwata R, Kilbourn MR, Pillai MR, Rajan MG, Wagner HN Jr, Zaknun JJ. Coenen HH, et al. Among authors: elsinga ph. Nucl Med Biol. 2010 Oct;37(7):727-40. doi: 10.1016/j.nucmedbio.2010.04.185. Nucl Med Biol. 2010. PMID: 20870148 Review.

2

Amino acids for the measurement of protein synthesis in vivo by PET.

Vaalburg W, Coenen HH, Crouzel C, Elsinga PH, Långström B, Lemaire C, Meyer GJ. Vaalburg W, et al. Among authors: elsinga ph. Int J Rad Appl Instrum B. 1992 Feb;19(2):227-37. doi: 10.1016/0883-2897(92)90011-m. Int J Rad Appl Instrum B. 1992. PMID: 1601675 Review.

3

Comparison of 18F-FLT PET and 18F-FDG PET in esophageal cancer.

van Westreenen HL, Cobben DC, Jager PL, van Dullemen HM, Wesseling J, Elsinga PH, Plukker JT. van Westreenen HL, et al. Among authors: elsinga ph. J Nucl Med. 2005 Mar;46(3):400-4. J Nucl Med. 2005. PMID: 15750150 Free article. Clinical Trial.

4

PET studies with L-[1-11C]tyrosine, L-[methyl-11C]methionine and 18F-fluorodeoxyglucose in prolactinomas in relation to bromocryptine treatment.

Daemen BJ, Zwertbroek R, Elsinga PH, Paans AM, Doorenbos H, Vaalburg W. Daemen BJ, et al. Among authors: elsinga ph. Eur J Nucl Med. 1991;18(7):453-60. doi: 10.1007/BF00181283. Eur J Nucl Med. 1991. PMID: 1915472

5

Carbon-11 choline or FDG-PET for staging of oesophageal cancer?

Jager PL, Que TH, Vaalburg W, Pruim J, Elsinga P, Plukker JT. Jager PL, et al. Eur J Nucl Med. 2001 Dec;28(12):1845-9. doi: 10.1007/s002590100655. Epub 2001 Oct 13. Eur J Nucl Med. 2001. PMID: 11734925

6

Comparison of (11)C-choline and (18)F-FDG PET in primary diagnosis and staging of patients with thoracic cancer.

Pieterman RM, Que TH, Elsinga PH, Pruim J, van Putten JW, Willemsen AT, Vaalburg W, Groen HJ. Pieterman RM, et al. Among authors: elsinga ph. J Nucl Med. 2002 Feb;43(2):167-72. J Nucl Med. 2002. PMID: 11850480 Free article.

7

18F-FLT PET for visualization of laryngeal cancer: comparison with 18F-FDG PET.

Cobben DC, van der Laan BF, Maas B, Vaalburg W, Suurmeijer AJ, Hoekstra HJ, Jager PL, Elsinga PH. Cobben DC, et al. Among authors: elsinga ph. J Nucl Med. 2004 Feb;45(2):226-31. J Nucl Med. 2004. PMID: 14960640 Free article.

8

Selectivity of 18F-FLT and 18F-FDG for differentiating tumor from inflammation in a rodent model.

van Waarde A, Cobben DC, Suurmeijer AJ, Maas B, Vaalburg W, de Vries EF, Jager PL, Hoekstra HJ, Elsinga PH. van Waarde A, et al. Among authors: elsinga ph. J Nucl Med. 2004 Apr;45(4):695-700. J Nucl Med. 2004. PMID: 15073267 Free article.

9

Is 18F-3'-fluoro-3'-deoxy-L-thymidine useful for the staging and restaging of non-small cell lung cancer?

Cobben DC, Elsinga PH, Hoekstra HJ, Suurmeijer AJ, Vaalburg W, Maas B, Jager PL, Groen HM. Cobben DC, et al. Among authors: elsinga ph. J Nucl Med. 2004 Oct;45(10):1677-82. J Nucl Med. 2004. PMID: 15471832 Free article. Clinical Trial.

10

[18F]FLT-PET in oncology: current status and opportunities.

Been LB, Suurmeijer AJ, Cobben DC, Jager PL, Hoekstra HJ, Elsinga PH. Been LB, et al. Among authors: elsinga ph. Eur J Nucl Med Mol Imaging. 2004 Dec;31(12):1659-72. doi: 10.1007/s00259-004-1687-6. Eur J Nucl Med Mol Imaging. 2004. PMID: 15565331 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

262 results

Search Page